Menlo Park, CA ; 03/11/2020
Amount Funded: $15 Million
Type: Series A+
Lead Investor: NeoTribe Ventures, Hummingbird Ventures
Participating Investor(s): HOF Capital, Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, 500 Startups Istanbul
Total Funding to Date: $32.5 Million
Company Description: BillionToOne, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company’s patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. BillionToOne’s first product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother’s blood. BillionToOne was co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D.
What funding will be used for: To support the commercial expansion of UNITY™ to all US states, research and development of future diagnostics tests including liquid biopsy products.
“Since the launch of UNITY™ last summer, we faced a significant demand from the prenatal providers from community Ob/Gyns to top academic institutions throughout the US. We are planning to expand the capacity of our CLIA-licensed laboratory by more than 20x and our commercial team size up to 50 account executives to meet the demand. This additional funding will help us accelerate this expansion process.”
-Oguzhan Atay, Ph. D., co-founder/CEO, BillionToOne
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.